Prime C: NeuroSense on their ALS Treatment

Celecoxib is a non-steroidal anti-inflammatory drug, or NSAID. Ciprofloxacin is an antibiotic that is used to treat a number of bacterial infections. The former has been trialed unsuccessfully in ALS. However, according to preclinical evidence and a phase 1 trial conducted by Neurosense, a biotech company based in Israel and Cambridge, MA, these two FDA-approved drugs may hold some promise for people with ALS when combined into one treatment.

Neurosense’s formulation of these two drugs is known as Prime C. The first participants were recently enrolled in a Phase 2b trial of the treatment, and it is also currently undergoing a pharmacokinetic trial in healthy volunteers. Recently, several members of Neurosense’s team joined Endpoints to help us learn more about the company’s mission, the science behind prime C, and what’s next for the potential ALS Treatment.

Episode Guide:

1:22 – NeuroSense's Company Story

5:58 – The Science Behind Prime C

15:13 –Details about Prime C in Clinical Trials

Support the show: https://www.als.net/donate/

See omnystudio.com/listener for privacy information.